SB 211475, a metabolite of carvedilol, a novel antihypertensive agent, is a potent antioxidant

This publication has 16 references indexed in Scilit:

• Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents
  The American Journal of Cardiology, 1993
• Probucol as an antioxidant and antiatherogenic drug
  Free Radical Biology & Medicine, 1993
• Endothelin Receptors in Neural Systems
  Published by Elsevier ,1993
• Neuroprotective effects of carvedilol, a new antihypertensive agent, in cultured rat cerebellar neurons and in gerbil global brain ischemia.
  Stroke, 1992
• Antioxidant effects of calcium channel blockers against free radical injury in endothelial cells. Correlation of protection with preservation of glutathione levels.
  Circulation Research, 1992
• Lipid peroxide and transition metals are required for the toxicity of oxidized low density lipoprotein to cultured endothelial cells
  Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1991
• Carvedilol (Kredex®) Reduces Infarct Size in a Canine Model of Acute Myocardial Infarction
  Pharmacology, 1991
• Biochemical analysis of the activation of adherent neutrophils in vitro
  Tissue and Cell, 1988
• A Pharmacokinetic Study of Carvedilol (BM 14.190) in Elderly Subjects
  Journal of Cardiovascular Pharmacology, 1987
• Differential sensitivity of canine cardiac sarcolemmal and microsomal enzymes to inhibition by free radical-induced lipid peroxidation.
  Circulation Research, 1984